Deal Structure Guide · Lab & Diagnostics Company

How to Structure a Lab & Diagnostics Company Deal

From asset purchases tied to payer contract assignments to earnouts based on referring physician volume retention — here is how buyers and sellers in the clinical laboratory sector negotiate deals that close and hold together.

Acquiring or selling an independent clinical laboratory is one of the more structurally complex transactions in the lower middle market healthcare space. Unlike a simple service business, a lab deal must account for CLIA certification continuity, CAP accreditation transfer, payer contract assignment provisions, billing compliance liability, and equipment condition — all of which directly influence how the deal is structured and how risk is allocated between buyer and seller. Most lab acquisitions in the $1M–$5M revenue range close in one of three primary structures: asset purchases with regulatory milestone holdbacks, stock purchases with seller financing to maintain transition alignment, or earnout arrangements tied to post-close volume and contract retention. The right structure depends on the lab's regulatory history, revenue concentration, equipment age, and whether the seller's relationships with referring physicians are transferable. This guide breaks down each structure, shows how they look in practice, and gives actionable guidance for both buyers and operators preparing to go to market.

Find Lab & Diagnostics Company Businesses For Sale

Asset Purchase with Regulatory Milestone Holdback

The buyer acquires specific assets of the laboratory — equipment, contracts, licenses, goodwill, and customer relationships — rather than the legal entity itself. A portion of the purchase price (typically 10–15%) is held in escrow and released only after defined regulatory and contractual milestones are achieved, such as successful payer contract assignment, CLIA certification transfer, and state lab licensure approval under the new ownership entity.

70–80% at close, 10–15% in escrow released over 6–12 months upon regulatory and contract milestones, 5–10% seller note or earnout

Pros

Limits buyer exposure to pre-closing billing compliance liabilities, OIG issues, or undisclosed Medicaid audit obligations that remain with the seller entity
Escrow holdback creates a financial incentive for the seller to actively support payer contract reassignment and regulatory transition work post-close
Buyer can negotiate specific representations and warranties around CLIA status, CAP accreditation, and clean compliance history, reducing post-close surprise risk

Cons

Asset deals may trigger payer contract change-of-ownership clauses, requiring re-credentialing and contract assignment approval that can delay revenue flow by 60–120 days
CLIA certification does not automatically transfer — the buyer must apply for a new certificate of compliance under the acquiring entity, creating an operational gap if not planned carefully
Sellers may resist the holdback structure if they need full liquidity at close, especially in retirement-driven exits where the seller has no desire for continued involvement

Best for: Buyers concerned about hidden billing or regulatory liability in a founder-operated lab with limited compliance infrastructure, particularly when the selling entity has a multi-year Medicare or Medicaid billing history that has not been independently audited.

Stock Purchase with Seller Financing

The buyer acquires 100% of the equity in the laboratory entity, inheriting all assets, contracts, licenses, and liabilities as a going concern. The seller carries back 10–20% of the purchase price in the form of a subordinated promissory note, typically over 3–5 years at market interest rates, aligning the seller's financial interest with a smooth post-close transition of client relationships and key staff.

80–90% at close (SBA or conventional financing), 10–20% seller note over 3–5 years

Pros

Payer contracts and CLIA certification remain in the existing legal entity, avoiding reassignment triggers and re-credentialing delays that disrupt revenue continuity
Seller financing signals the seller's confidence in post-close performance and keeps them financially motivated to introduce the buyer to referring physicians and support staff retention
Simplifies deal closing mechanics compared to a full asset carve-out, particularly when the lab operates under long-term facility leases or equipment financing arrangements tied to the entity

Cons

Buyer assumes all historical liabilities of the entity, including any undisclosed Medicare billing issues, open CMS audits, or state regulatory violations — robust indemnification provisions and representations and warranties insurance are critical
Seller financing creates ongoing financial relationship with the former owner, which can become contentious if post-close performance disappoints or disputes arise over indemnification obligations
Lenders, including SBA lenders, may require a full compliance audit and clean billing history as a condition of financing a stock purchase in the clinical lab sector given elevated regulatory risk

Best for: Acquisitions where the lab has a long-established payer contract portfolio, clean OIG and CMS compliance history, and the seller's transition cooperation is essential to retaining referring physician volume — common in retirement-driven exits by pathologists or lab founders with 10-plus year operating track records.

Earnout Structure Tied to Volume and Contract Retention

A portion of the purchase price — typically 15–25% — is deferred and paid to the seller over 12–24 months based on the achievement of specific post-close performance metrics, most commonly the retention of specimen volume from top referring accounts and the successful renewal or assignment of key payer contracts. Earnout payments may be structured as quarterly or annual installments upon hitting defined thresholds.

65–75% at close, 15–25% earnout paid over 12–24 months based on volume and contract retention milestones

Pros

Bridges the valuation gap between buyer and seller when future revenue sustainability is uncertain, particularly when a small number of referring groups drive a disproportionate share of volume
Aligns seller incentives with post-close transition success, motivating the former owner to actively support physician relationship handoffs and staff retention during the earnout period
Allows buyers to pay a higher headline valuation while limiting downside risk if key accounts do not transfer or payer contracts renegotiate at lower reimbursement rates after closing

Cons

Earnout disputes are among the most common sources of post-close litigation in healthcare M&A — poorly defined metrics, ambiguous measurement periods, and buyer operational decisions that affect performance create significant conflict potential
Sellers in retirement-oriented exits may be unwilling to remain operationally involved for 12–24 months, limiting the earnout's effectiveness as a transition tool
Complex to administer if the acquired lab is integrated into a larger platform, making it difficult to isolate the performance metrics tied to the earnout from the broader entity's operations

Best for: Transactions where one or two referring physician groups or hospital contracts represent 35–50% of specimen volume, making revenue sustainability genuinely uncertain, and where the seller's continued involvement in account management during the transition period is both feasible and necessary.

SBA 7(a) Financed Acquisition

An SBA 7(a) loan finances up to 90% of the purchase price, enabling buyers — particularly first-time healthcare operators or entrepreneurial clinical professionals — to acquire a CLIA-certified laboratory with as little as 10% equity injection. The SBA structure typically requires a 10-year loan term for goodwill-heavy acquisitions and may mandate seller standby financing for a portion of any seller note during the initial loan period.

80–90% SBA financing, 5–10% buyer equity, 5–10% seller note (on standby per SBA guidelines)

Pros

Dramatically reduces the equity required at close, making profitable independent labs accessible to qualified buyers who lack institutional capital but have relevant healthcare or clinical operations backgrounds
SBA loans for lab acquisitions are fully amortizing with no balloon payments, providing predictable debt service aligned with the recurring revenue nature of specimen-based laboratory businesses
Seller standby provisions on any seller note (typically 2 years of interest-only standby required by SBA) effectively defer a portion of seller proceeds, aligning incentives without a formal earnout structure

Cons

SBA underwriting for clinical laboratory acquisitions is rigorous — lenders will scrutinize CLIA compliance status, billing history, payer contract stability, and equipment condition, and a lab with any open audits or regulatory issues will likely be declined
Personal guarantee requirements and collateral obligations can be burdensome for buyers, particularly when the lab's primary assets are intangible (goodwill, contracts, accreditations) rather than hard assets
SBA loan processing timelines of 60–90 days can introduce closing risk in competitive situations where sellers are entertaining multiple offers from well-capitalized strategic or PE buyers

Best for: Entrepreneurial buyers — including clinical lab directors, healthcare administrators, or physician entrepreneurs — acquiring a single CLIA-certified lab platform with clean regulatory history, stable payer contracts, and EBITDA margins in the 20–30% range that support SBA debt service coverage requirements.

Sample Deal Structures

Toxicology Lab Acquisition — Retirement Exit by Founder-Director

$2,800,000

$2,240,000 (80%) funded via SBA 7(a) loan at close; $280,000 (10%) buyer equity injection; $280,000 (10%) seller promissory note at 6.5% interest over 5 years, with 24-month interest-only standby per SBA requirements

Asset purchase structure. Seller retains entity liability for pre-close billing history. $280,000 escrow holdback from SBA proceeds released in two tranches: $140,000 upon successful CLIA certification transfer and Medicare provider enrollment under new entity (estimated 90 days), and $140,000 upon assignment of top 3 payer contracts including Medicare, Medicaid, and primary commercial insurer. Seller commits to 12-month transition consulting at $6,000/month to support referring physician introductions and staff retention. Lab director employment agreement offered to current director at market compensation to eliminate key-person risk.

Regional Reference Lab Add-On for PE-Backed Platform

$4,500,000

$3,150,000 (70%) cash at close funded from PE platform balance sheet; $900,000 (20%) seller note at 7% over 4 years, full payment (not on standby); $450,000 (10%) earnout paid in two equal installments at 12 and 24 months post-close

Stock purchase structure used to preserve existing payer contracts and CLIA certification continuity within the acquired entity. Earnout of $450,000 conditioned on: (a) aggregate specimen volume from top 5 referring physician groups not declining more than 15% from trailing 12-month baseline in Year 1, and (b) successful renewal of the hospital system outreach contract (representing 22% of revenue) at reimbursement rates no more than 10% below current contracted rates. Seller provides comprehensive reps and warranties; buyer purchases representations and warranties insurance with a $500,000 retention. Seller remains as non-executive clinical advisor for 18 months at $8,500/month.

Specialty Molecular Diagnostics Lab — Physician Entrepreneur Exit

$3,200,000

$2,240,000 (70%) conventional bank financing (non-SBA) at close; $640,000 (20%) seller note at 6% over 5 years; $320,000 (10%) earnout over 18 months

Asset purchase. Purchase price reflects 5.1x adjusted EBITDA of $627,000 on $2.4M revenue, a premium driven by the lab's proprietary molecular assay panel and CAP accreditation. Earnout tied to retention of two hospital system contracts that together represent 38% of revenue — $160,000 payable at 9 months if both contracts remain active and unmodified, $160,000 at 18 months if combined contract revenue has not declined more than 10% from closing baseline. Equipment escrow of $120,000 established to fund replacement of two aging analyzers identified in pre-close equipment assessment, released to seller if buyer does not require replacement within 12 months. Seller-physician agrees to 24-month non-compete covering 75-mile radius.

Negotiation Tips for Lab & Diagnostics Company Deals

1Before entering LOI negotiations, obtain an independent CLIA and billing compliance audit — this gives you objective leverage to negotiate escrow holdbacks or price adjustments based on actual regulatory risk rather than seller representations alone, and it accelerates SBA underwriting if financing is involved.
2In any structure involving payer contract assignment, map every contract's change-of-ownership provision before signing the LOI. Some Medicare Advantage and commercial managed care contracts allow unilateral termination upon ownership change — identifying these early lets you negotiate a transition services agreement that keeps the seller credentialed and billing under the old entity during the re-enrollment period.
3When negotiating earnout metrics for a lab acquisition, insist on measuring specimen volume by referring account rather than total revenue — revenue can be manipulated by test mix changes or payer rate shifts, but specimen volume directly reflects whether the seller's physician relationships have actually transferred to the new ownership.
4Structure seller financing with a cross-default provision tied to the seller's indemnification obligations. If a post-close billing audit reveals undisclosed Medicare overpayments, you want the right to offset repayment obligations against the outstanding seller note rather than pursuing separate litigation while also writing checks to the seller.
5For SBA-financed lab acquisitions, engage an SBA lender with documented healthcare services experience early — preferably a preferred lender program (PLP) lender who can process in-house. Labs with reimbursement concentration in Medicare or Medicaid will face additional underwriting scrutiny, and a lender unfamiliar with clinical laboratory economics may decline or delay deals that are fundamentally sound.
6Always negotiate a lab director retention package as a closing condition rather than a post-close aspiration. If the lab director — who holds the CLIA certificate of compliance and maintains relationships with referring clinicians — departs within 90 days of close, you face both a regulatory crisis and a client retention crisis simultaneously. Tie a meaningful portion of any seller earnout or consulting fee to lab director retention milestones.

Find Lab & Diagnostics Company Businesses For Sale

Pre-screened targets ready for your deal structure — free to join.

Get Deal Flow

Frequently Asked Questions

Why do most clinical lab acquisitions use an asset purchase rather than a stock purchase?

Buyers prefer asset purchases because they avoid inheriting historical billing liabilities — Medicare overpayment obligations, open CMS audits, or prior Anti-Kickback Statute exposure can represent significant undisclosed risk in labs that have billed under the same entity for many years. In a stock purchase, the buyer steps into the shoes of the legal entity and assumes all of that history. Asset purchases let the buyer take the business forward without taking the legacy risk. The trade-off is that payer contracts and the CLIA certificate must be reassigned or reapplied under the new entity, which takes time and creates a revenue gap. Stock purchases are more common when the lab has a genuinely clean compliance history and the buyer needs contract continuity to avoid disrupting revenue.

How does a CLIA certification transfer work during a lab acquisition, and how long does it take?

A CLIA certificate does not transfer automatically — when ownership changes, the new entity must apply for its own CLIA certificate of compliance through CMS or the applicable state survey agency. This typically takes 60–120 days. During that period, if the lab is structured as an asset purchase, the seller's entity must remain active and the seller must allow the buyer to operate under a management services agreement, with the seller still holding the CLIA certificate. Many deal structures include a transition services agreement specifically to cover this gap. CAP accreditation is separate and requires the new entity to undergo its own inspection cycle. Buyers should budget for this operational overlap period and structure the purchase price escrow release to account for it.

What is a realistic earnout structure for a lab with high referring physician concentration?

If one or two physician groups represent 35–50% of specimen volume, expect earnout structures of 15–25% of the purchase price paid over 12–24 months based on volume retention thresholds. A common structure ties 50% of the earnout to 12-month volume retention at 85–90% of the pre-close baseline, and the remaining 50% to 24-month retention at 80–85% of baseline — acknowledging that some natural attrition is expected while still protecting the buyer from a full account defection. Earnout metrics should always be specimen-count based rather than revenue based, and the agreement must specify exactly how volume is measured, what counts as an excluded event (payer rate changes, market-wide reimbursement cuts), and how disputes are resolved to avoid post-close litigation.

Can I use an SBA loan to buy a clinical laboratory business?

Yes, clinical laboratory acquisitions are SBA-eligible provided the business meets standard SBA size and for-profit requirements. SBA 7(a) loans are the most common structure, financing up to 90% of the purchase price with a 10-year term for goodwill-heavy deals. However, SBA lenders will closely scrutinize the lab's CLIA compliance status, Medicare and Medicaid billing history, payer contract stability, and debt service coverage — typically requiring 1.25x DSCR minimum. Any open CMS audits, OIG exclusions, or prior billing settlements are likely to be disqualifying without resolution. Buyers pursuing SBA financing should engage a PLP lender with healthcare services experience and have a third-party compliance audit ready as part of the loan package.

How do payer contract assignment clauses affect deal structure and timing?

Payer contract assignment clauses are one of the most deal-critical issues in clinical lab M&A. Most Medicare and Medicaid participation agreements require notification and re-enrollment under the new entity — this is not optional and can take 90–180 days. Commercial managed care contracts vary widely: some allow assignment with consent, some require a new contract negotiation, and some have termination-for-change-of-ownership provisions. Buyers should conduct a full contract review during due diligence and map every payer contract against its assignment language before signing an LOI. Where contracts represent material revenue and reassignment is uncertain, buyers should structure escrow holdbacks or earnout conditions tied to successful contract continuity rather than assuming assignment will happen automatically after close.

What is a realistic valuation multiple for a CLIA-certified independent lab in the lower middle market?

Independent clinical labs with $1M–$5M in revenue and EBITDA margins of 15–30% typically trade at 3.5x–6.5x adjusted EBITDA. Labs at the lower end of that range generally have equipment condition issues, high revenue concentration, or reimbursement exposure to routine tests heavily impacted by PAMA rate cuts. Labs commanding 5x–6.5x typically offer differentiated specialty or molecular testing capabilities, CAP accreditation, clean compliance histories, diversified referring provider bases, and strong revenue cycle metrics. The presence of an SBA-eligible deal structure, a clean billing audit, and documented equipment maintenance records all support higher valuations by reducing buyer-perceived risk and expanding the pool of qualified buyers who can finance the transaction.

More Lab & Diagnostics Company Guides

Acquire a Lab & Diagnostics Company Business →Valuation Guide →SBA Loan Guide →LOI Template →Due Diligence →

More Deal Structure Guides

Landscaping →Language School →Laundromat →Law Firm →Lawn Care Service →Lead & Asbestos Abatement →Learning Center →Light Industrial Staffing →Browse all deal structure guides →

Start Finding Lab & Diagnostics Company Deals Today — Free to Join

Find the right target, structure the deal, and close with confidence.

Create your free account

No credit card required